In recent years, lymphangiogenesis, the process of lymphatic vessel formation from existing lymph vessels, has been demonstrated to have a significant role in diverse pathologies, including cancer metastasis, organ graft rejection, and lymphedema. Our understanding of the mechanisms of lymphangiogenesis has advanced on the heels of studies demonstrating vascular endothelial growth factor C as a central pro‐lymphangiogenic regulator and others identifying multiple lymphatic endothelial biomarkers. Despite these breakthroughs and a growing appreciation of the signaling events that govern the lymphangiogenic process, there are no FDA‐approved drugs that target lymphangiogenesis. In this review, we reflect on the lessons available from the development of antiangiogenic therapies (26 FDA‐approved drugs to date), review current lymphangiogenesis research including nanotechnology in therapeutic drug delivery and imaging, and discuss molecules in the lymphangiogenic pathway that are promising therapeutic targets.

中文翻译：

---

潜在的淋巴管生成疗法：从当前的抗血管生成疗法中学习——综述

近年来，淋巴管生成，即从现有淋巴管形成淋巴管的过程，已被证明在多种病理学中具有重要作用，包括癌症转移、器官移植排斥和淋巴水肿。我们对淋巴管生成机制的理解在研究证明血管内皮生长因子 C 作为中央前淋巴管生成调节剂和其他确定多种淋巴管内皮生物标志物之后取得了进展。尽管取得了这些突破，并且对控制淋巴管生成过程的信号事件越来越了解，但没有 FDA 批准的靶向淋巴管生成的药物。在这篇综述中，我们回顾了抗血管生成疗法（迄今为止已获得 26 种 FDA 批准的药物）开发的经验教训，